GlassScriptPhysician profile
Barbara A Winfield
NPI 1992898720
$7,575.03
in general payments reported to CMS, 2019-2025
55 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,727 · 2020: $1,281 · 2021: $1,379 · 2022: $865 · 2023: $519 · 2024: $1,009 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $837.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $774.67 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $684.40 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $614.68 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $390.10 | 2019-2024 | Veozah |
| Lilly USA, LLC | $373.53 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $353.89 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $323.85 | 2019-2025 | |
| Amgen INC. | $312.25 | 2019-2025 | Otezla, Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $276.27 | 2020-2025 | Zoryve, Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.89 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $179.06 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $153.86 | 2019-2025 | Rexulti |
| Lundbeck LLC | $147.51 | 2021-2025 | Rexulti, Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.11 | 2019-2025 | Xifaxan |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Winfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.